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Confronted with a competitive or recreational
athlete, the physician has to discriminate between
benign, paraphysiological and pathological ar-
rhythmias. Benign arrhythmias do not represent a
risk for SCD, nor do they induce haemodynamic
consequences during athletic activities. These
arrhythmias are not markers for heart disease.
Paraphysiological arrhythmias are related to
athletic performance. Long periods of endurance
training induce changes in rhythm, conduction
and repolarisation. These changes are fillly
reversible and disappear when the sport is
terminated. Pathological arrhythmias have
haemodynamic consequences and express disease,
such as sick sinus syndrome, cardiomyopathy or
inverse consequences of physical training.
Arrhythmias can be classified as bradyarrhythmias
and tachyarrhythmias. Conduction disorders can
be seen in fast as well as in slow arrhythmnias. (Neth
HeartJ2004;12:214-22.)
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Bradyarrhythmias
Sinus bradycardia
Sinus bradycardia is defined as a rhythm lower than
50 beats/min. Related to the type ofsporting activity
50 to 90% of athletes show sinus bradycardia with a
mean heart rate of50 beats/min.' Sinus bradycardias
with rates of25 beats/min are recorded especially at
night. Sinus arrhythmia is a very common finding.
There is a wide range in prevalence ofsinus arrhythmia
in athletes, ranging from 13 to 91%. Asymptomatic
sinoatrial pauses ofbetween 2 to 3 sec are commonly
recorded in endurance athletes.2'3 A resting sinus rate
below 40 beats/min that does not increase more than
100 beats/min during exercise is an abnormal finding
and cardiological evaluation is indicated. ECG and
Holter monitoring can be used and sometimes electro-
physiology studies (EPS) in specific cases. Symptomatic
pauses ofmore than 3 sec are abnormal4 and require
cardiological evaluation including ECG, Holter
monitoring, exercise testing, echocardiography and EPS.
Sick sinus syndrome
The prevalence of this disorder is not well defined. In
the literature, a prevalence of 0.17% is mentioned by
Kulbertus, et al.5 Several intrinsic as well as extrinsic
factors can cause sick sinus syndrome. Longstanding
isotonic loading causes volume stress ofthe myocardium
and results in a dilatation ofthe heart chambers. It has
been suggested that the process ofdilatation ofthe atria
and ventricles in combination with extreme vagal
stimulation and changes in the collagen/fibrosis ratio
could be a substrate for the development of sick sinus
syndrome.6 The changes at atrial level could disrupt the
interaction between pacemaker cells. It is likely that
genetic predisposition contributes to this syndrome.
Recommendation
Athletes with presyncope or syncope should not
participate in sports because loss ofconsciousness may
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be hazardous for the athlete himselfor others. Athletes
with a normal or structurally abnormal heart in which
the bradyarrhythmia is asymptomatic and disappears
with exercise and in which the (sinus) bradycardia rate
increases appropriately during exercise may participate
in all competitive sports. They have to be re-examined
periodically to determine that training does not
aggravate the bradyarrhythmia.
Athletes with symptoms such as impaired con-
sciousness and fatigue related to the arrhythmia should
be treated and should not participate in sports because
loss ofconsciousness may be hazardous for the athlete
himself or others. If the athlete is asymptomatic for a
six-month period during treatment, he may participate
in all competitive sports after cardiological re-exam-
ination. Athletes with symptomatic tachy-brady syn-
drome or an inappropriate increase of exercise heart
rate should be treated. Ifasymptomatic for six months,
they may participate in low-intensity competitive
sports. Athletes with pacemakers should not engage
in sports with danger of bodily collision. (Class IC:
field hockey, soccer. Class IIA: diving, motorcycling.
Class IIB: rugby. Class IIC: basketball, ice hockey,
team handball. Class IIIA: bobsledding, karate, judo,
water-skiing. Class IIIB: downhill skiing, wrestling.
Class IIIC: boxing).
Disorders of atrioventricular conduction
In the athletic population AV conduction disorders
are not uncommon and it is assumed that these
disorders are related to the intensity and length ofthe
training period.7
First-degree AVblock
First-degree AV block is a benign conduction ab-
normality and the incidence is between 10 and 33% in
athletes compared with 0.65% in the general popu-
lation.3
Second-degree AVblock
Second-degree AV block could be a sign of organic
heart disease, but is not uncommon in endurance
athletes. The incidence of type I second-degree AV
block is between 23 and 40% in athletes compared
with 5.7% in a normal population.3 Exercise-induced
second-degree AV block is uncommon and clinically
important because it can result in significant dyspnoea
or syncope during sportng activities.
Recommendation
Athletes with normal hearts and no worsening or
improvement of the AV block with exercise may
participate in all competitive sports. Athletes with
structural heart disease, inwhomAV block disappears
or does not worsen with exercise or recovery, may
participate in all competitive sports, as determined by
limitations ofthe cardiac abnormality. Athletes without
symptoms, in whom the AV block initially appears to
worsen with exercise or during the recovery period
should undergo cardiological evaluation. If the AV
block is infranodal permanent pacing may be required.
Second-degree type IIAVblock
This type ofAV block occurs in 8% of athletes.3 This
abnormality is often related to a structural heart
disorder. Evaluation ofathletes with this abnormality
is similar to athletes with type I AV block.
Recommendation
Athletes with intrahisian and infrahisian type II second
degree AV block should be treated with permanent
pacing before athletic activity.
Acquired complete heart block
Acquired complete heart block is rare in athletes. It
can be permanent or transient. The incidence lies
between 0.02 and 0.00017%. In a normal population
the incidence is 0.0002%.3 Ifthird degree AV block is
present evaluation is necessary to exclude underlying
heart disease. In some cases vagal over-stimulation
plays an important role and a period ofdetraining could
be successful in the management of a symptomatic
athlete with a third degree AV block.
Recommendation
Athletes with normal hearts and asymptomatic
transient complete AV block that disappears during
exercise andwho show an appropriate increase in heart
rate may participate in all competitive sports. Athletes
with symptoms of fatigue, near syncope or syncope
should have a pacemaker implanted before they par-
ticipate in competitive sports.
Atrioventricular escape andjunctional rhythm
Atrioventricular escape and junctional rhythms are
common arrhythmias in athletes.3 They are the result of
training and vagal over-stimulation. Clinical evaluation
and recommendations are the same as those for
symptomatic athletes with sinus node dysfunction.
Recommendation
Athletes with normal hearts and normal heart rate
response to activity without sustainedAVnodal orAV
junctional tachycardia may participate in all competitive
sports. Athletes with structural heart disease may
participate in competitive sports, depending on the
limitations ofthe structural heart disease.
Bundle branch block
The mean QRS width in athletes is between 90 and 100
msec. Incomplete right bundle branch block (RBBB)
is common in highly trained athletes. For male athletes
the incidence is 16.7% and for female athletes it is 0.2%.
The incidence of a complete RBBB in female athletes
is 0.2% and for male athletes 1.2%.8 Complete left
bundle branch block (LBBB) is uncommon in athletes
and is probably more likely to be associated with under-
lying heart disease than RBBB.9"10 Exercise-induced
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LBBB is a rare electrocardiographic observation in
athletes. LBBB may represent heart disease and
requires full examination.
Recommendation
Athletes with asymptomatic, incomplete RBBB and
no underlying heart disease may participate in all
competitive sports, as may athletes with an RBBB and
an LBBB (with or without left-axis deviation), inwhom
no AV block develops with exercise and who have no
symptoms. Athletes with a normal HV interval and a
normal AV conduction response to pacing have no
restrictions either. Athletes with significant prolongation
of the HV interval (>90 ms) or with a His-Purkinje
block should have a permanent pacemaker implanted
before sport activity. Athletes with interventricular
conduction abnormality and structural heart disease
may participate in competitive sports, depending on the
lirnitations ofthe underlying heart disease.
QT interval
In general the QT interval and the corrected QT is
prolonged in athletes and is caused by the relative
bradycardia.3 The QT interval in women is more
prolonged at low heart rates than in men." Patho-
logical prolongation ofthe QT interval occurs in some
electrolyte-related disorders, diet deficiencies and abuse
ofdrugs. Some medicaments could induce torsade de
pointes arrhythmias. A lack ofappropriate shortening
of the QTc interval during exercise could suggest
LQTS. The predictive value of the QT dispersion in
relation to ventricular arrhythmias in athletes is subject
for debate.'2
Recommendation
Athletes with a prolonged QT and QTc interval, in
whom the interval prolongation persists during
exercise, could be at risk for LQTS and should not
participate in sporting activities even in the absence of
documented ventricular arrhythmias.
Tachyarrhythmias
Sinus node reentry tachycardia and atrial tachycardia
Sinus node reentry tachycardia is an uncommon
finding in athletes. The average heart rate is between
130 and 140 beats/min. Atrial tachycardia is extremely
rare in athletes. The atrial rate is generally between 150
and 200 beats/min. Underlying heart disease could
possibly be a cardiomyopathy. Automaticity or a
reentryphenomenon can cause atrial tachycardia which
develops after surgery. RF catheter ablation could be
an effective therapeutic option. Evaluation can be done
by ECG, Holter monitoring and echocardiography.
Recommendation
Athletes with atrial tachycardia or sinus node reentry
tachycardia should first be considered for EPS and RF
catheter ablation. If there is no recurrence of the
arrhythmia after four to six months and if there is no
structural heart disease, the athlete may participate in
all competitive sports. Athletes with atrial tachycardia
without structural heart disease, with ventricular rates
comparable with those of an appropriate sinus
tachycardia during physical activity with or without
therapy, have no restrictions either. Athletes with atrial
tachycardia and structural underlying heart disease
should only participate in competitive sports consistent
with the limitations ofthe heart disease.
AV nodal reentry tachycardia
The prevalence of this arrhythmia in the athletic
population is equal to that in the normal population
and accounts for about 50% of all cases for supra-
ventricular tachycardia. Evaluation is carried out by
ECG, echocardiogram to exclude structural heart
disease and a stress test. EPS could be helpful if the
diagnosis is uncertain. The preferred therapy is RF
catheter ablation.
Recommendation
In the absence ofstructural heart disease, athletes with
asymptomatic nonsustained episodes ofthis arrhythmia
that are not induced by exercise and do not aggravate
in duration during exercise may participate in all
competitive sports. Athletes with symptomatic
arrhythmias or with reproducible exercise-induced
tachycardia should be treated with RF catheter
ablation. If there is no recurrence four to six months
after ablation all competitive sports are allowed.
Athletes with structural heart disease after undergoing
RF catheter ablation may only participate in com-
petitive sports in accordance with the limitations of
the heart disease.
Atrioventricular circus movement tachycardia,
including Wolff-Parkinson-White syndrome
Atrioventricular circus movement tachycardia occurs
in 40% of cases of supraventricular tachycardia.
Orthodromic circus movement tachycardia occurs in
90 to 95% and antidromic circus tachycardia in 5 to
10% of cases. A concealed AV-bypass tract can be the
cause ofthe circus movement tachycardia (30 to 40%).
In case of an atrioventricular reentry tachycardia the
extra pathway is usually located in the left lateral free wall
(50%) (posteroseptal 30%, right anteroseptal 10% and
right lateral 10%).1" The prevalence ofatrial fibrillation
in patients with atrioventricular reentry tachycardia is
40%.9 For evaluation, ECG, exercise test and 24-hour
Holter during sport activities are indicated and echo-
cardiography is used to exdude underlying heart disease.
Recommendation
Athletes with symptomatic atrioventricular reentry
tachycardia should undergo EPS and RF catheter
ablation of the accessory pathway regardless of its
conduction properties. Athletes without structural
heart disease and with atrioventricular reentry tachy-
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cardia and concealed pathways have similar recom-
mendations to those with atrioventricular nodal reentry
tachycardia. Athletes with episodes ofatrial fibrillation
whose maximal ventricular rate at rest (without
therapy) due to conduction over the accessory pathway
is <240 beats/min and who have no episodes of syn-
cope or near syncope and have no structural heart
disease appear to have low risk ofsudden cardiac death
and may participate in all competitive sports. Athletes
with syncope or near syncope or episodes of atrial
flutter or atrial fibrillation whose maximal ventricular
rate at rest (without therapy) due to conduction over
the accessory pathway exceeds 240 beats/min, should
be scheduled for ablation and are restricted to Class
IA sports. After successful ablation, athletes who are
asymptomatic and with no recurrence of the tachy-
cardia for three to six months have no restrictions for
competitive sports.'4 Athletes with underlying heart
disease may only participate in competitive sports in
accordance with the limitations ofthe heart disease.
Atrial fibrillation and flutter
Prevalence ofatrial fibrillation in athletes is higher than
in the general population ofthe same age and is usually
not related to structural heart disease.3""'6 In most
cases atrial fibrillation could be classified as lone atrial
fibrillation. Long-term vigorous exercise, however,
may trigger atrial fibrillation.'7 Atrial fibrillation in
young healthy athletes can be induced vagally and can
be due to an overtraining syndrome. Atrial fibrillation
could be the first symptom of a more serious under-
lying heart disease. There are data that lifelong en-
durance training induces more arrhythmias than a
sedentary life.'8 ECG, exercise test and 24-hour Holter
during sport activity are used to evaluate atrial fibril-
lation/flutter and echocardiography can be performed
to exclude underlying heart disease.
Recommendation
Athletes with atrial fibrillation in the absence ofWPW
and other structural heart disease who maintain a
ventricular rate comparable with that ofan appropriate
sinus tachycardia during physical activity with or
without therapy may participate in all competitive
sports. It is necessary to evaluate the arrhythmia therapy
by Holter monitoring during sport activities. For
evaluating possible proarrhythmic activity of the
antiarrhythmic drugs, an exercise test should be done
one week after starting the specific drug.
Athletes who have atrial fibrillation in combination
with an underlying heart disease and appropriate in-
crease in ventricular rate during activity may participate
in sports dependent on the limitations of their
structural heart disease.
Therapeutic remarks
Treatment of athletes with atrial fibrillation is initially
no different from the treatment ofnontrained subjects.
The application of the recommendations for atrial
fibrillation is essentially the same for athletes and
nontrained subjects.9"4"9 Underlying heart disease and
causal factors such as rheumatic heart disease, mitral
valve prolapse, hyperthyroidism, pulmonary embolism,
alcoholism and drugs have to be determined. Medical
therapy, anticoagulation, antiplatelet therapy and
electrical cardioversion of atrial fibrillation are not
different in an athlete population. Athleteswho require
anticoagulation should not participate in sports because
ofrisk ofbodily collision initiating serious bleeding.9"4
Class IC antiarrhythmic drugs are effective in vagal-
induced atrial fibrillation while exercise-provoked atrial
fibrillation could be successfully treated with a low dose
of [-blocker or sotalol. In a substantial number of
athletes sotalol has proved to be ineffective and in a
subgroup of athletes it even worsens symptoms and
provokes side effects. The bradycardia in some athletes
is one ofthe problems and makes it difficult to choose
the right therapy, if drug-therapy has failed. Focal
ablation or Maze procedure is possibly a better option.
Training and atrialfibrillation
Atrial fibrillation can be seen as a manifestation ofthe
overtraining syndrome and can disappear after
interruption training. Training should be interrupted
for three to five days. After this rest period the training
schedule can be resumed with the restriction that the
total volume ofthe training should be lowered to half
the usual programme. Each training session is alter-
nated with a rest day and one competition day should
be substituted for a training session. In severe over-
training, the training has to be interrupted for several
weeks and a low-intensity training could be advised.20'2'
After an interruption ofcompetition and training atrial
fibrillation can disappear in some athletes. It is recom-
mended to evaluate the effect after a period of eight
weeks. With an adrenergically induced atrial fibrillation,
high-intensity training bouts should be avoided.
Atrial flutter is uncommon in a young athletic
population. Paroxysmal atrial flutter can occur in the
absence ofstructural heart disease, while chronic atrial
flutter is likely to be associated with underlying heart
disease. In 20 to 30% ofcases athletes also show atrial
fibrillation. Atrial flutter can be classified as common
and uncommon. The flutter rate ofthe common type
is 250 to 350 beats/min. For the uncommon type the
rate is between 350 to 450 beats/min. A rapid 1:1
ventricular response can occur with the use ofIA and
IC antiarrhythmic drugs that slow down the atrial
flutter or by enhancing AV conduction with exercise.
RF ablation is the preferred therapy for the common
type of atrial flutter. The uncommon type could be
treated medically but RF ablation is also possible. For
evaluation, see atrial fibrillation.
Recommendation
Athletes with the common form ofatrial flutter should
be considered for RF catheter ablation. After ablation
they may participate in low-intensity sports and ifthere
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is no evidence of arrhythmia recurrence after four to
six months all competitive sports are permitted.
Athletes with the uncommon form of atrial flutter
should be treated medically.
Athletes on medical treatment without structural
heart disease and who maintain an appropriate ven-
tricular rate during exercise may participate in low-
intensity sports. Full participation in all categories is
allowed ifthere is no evidence ofrecurrence arrhythmia
for a period offour to six months. Athletes with atrial
flutter and structural heart disease may participate in
low-intensity sports depending on the limitations of
the heart disease. Athletes on medical treatment should
be examined annually.
Ventricular arrhythmias
Ventricular tachycardia is uncommon in athletes and
frequently occurs in the presence of structural heart
disease. Ventricular tachyarrhythmias can occur in
the absence of (detectable) heart disease. Because of
the preservation of normal cardiac function, these
arrhythmias are generally well tolerated. These ven-
tricular arrhythmias are usually associated with a
favourable prognosis in normal individuals but they
could have a clear impact on athletic performance
and career. Occasional deaths reported in athletes
with apparently idiopathic ventricular arrhythmias
might not permit calling this arrhythmia benign.
Right ventricular outflow tract tachycardia
Right ventricular outflow tachycardia (RVOT) is
characterised by a repetitive monomorphic tachycardia
with a left bundle branch block and inferior axis and
has to be distinguished from arrhythmogenic right
ventricular dysplasia. The athlete with RVOT tachy-
cardia is often female, aged between 20 to 35.22 The
arrhythmia starts under conditions ofemotional stress
or exercise and in most cases is well tolerated. It can
occur during deceleration of the sinus rate following
exertion. The arrhythmia is cyclic AMP mediated
triggered activity and abnormal automaticity rather
than reentry mechanism. To evaluate this condition,
ECG, signal-averaged ECG, Holter monitoring during
sport activity, exercise test, echocardiography, coronary
angiography, magnetic resonance imaging and EPS
can be used. The therapy ofchoice is ablation. Long-
term antiarrhythmic therapy is not acceptable in this
young population because of either side effects or
dissatisfaction with the need for long-term medication.
There is variable response to treatment with ,8-blockers.
Recommendation
Athletes with nonsustained or sustained ventricular
tachycardia should not compete in sports until they
are fully evaluated and treated. Athletes without
structural heart disease and PVCs that disappear during
exercise may participate in all forms of competitive
sports. Should the PVCs increase in frequency during
exercise and deteriorate to VT with symptoms of
impaired consciousness, extreme fatigue or dyspnoea,
then the athlete should only participate in low-intensity
sports. Athletes with symptomatic PVCs that are
suppressed by drug therapy should only participate in
low-intensity sports. Athletes with asymptomatic
monomorphic nonsustained ventricular tachycardia
(heart rates <150 beats/min) and no structural heart
disease may participate in all competitive sports if
exercise testing demonstrates suppression of the
ventricular tachycardia or no significant worsening
compared with baseline. Cardiological examination
every six months is needed.
Athletes with no structural heart disease and treated
for sustained or nonsustained VT should not compete
in all sports for at least six months after the last episode
ofVT. In some cases participation in low-intensity
sports is permitted. If there is no clinical recurrence
and the VT is not inducible by exercise and/or EPS
and the athlete has no structural heart disease all
competitive sports are permitted.
For athletes with structural heart disease and
ventricular tachycardias, moderate and high-intensity
competitive sports are contraindicated regardless of
whether the ventricular tachycardia is suppressed or
not. Only low-intensity sports are allowed.
All moderate and high-intensity sports are usually
contraindicated in athletes with an implantable cardio-
verter defibrillator.9
Left ventricular outflow tract tachycardia (LVOT)
These tachycardias show an RBBB with an inferior axis
on the ECG. Some of these arrhythmias originate in
the epicardial regions of the left ventricle at a level of
the left main coronary artery.22 The behaviour is similar
to that ofRVOT compatible with cyclicAMP mediated
triggered activity and delayed afterdepolarisations.
ECG, signal-averaged ECG, Holter monitoring during
sport activity, exercise test, echocardiography, coronary
angiography, magnetic resonance imaging and EPS
and indicated to evaluate these arrhythmias.
Recommendation
See recommendations for right ventricular outflow
tract tachycardia.
Idiopathic left ventricular tachycardia (ILVT)
Athletes showing idiopathic left ventricular tachycardia
or fascicular tachycardia are between 20 and 40 years
old. There is a variable association with physical activity
and the arrhythmia is not usually provoked by exercise.
Athletes have symptoms of palpitations, syncope is
uncommon and cardiac arrest is rare. The ECG has an
RBBB and left superior axis morphology and a
relatively narrow QRS duration. ILVT can be provoked
by programmed stimulation and sometimes by
isoproterenol infusion. Verapamil could terminate this
arrhythmia. Catheter ablation is now the therapy of
choice. The prognosis is in general benign. To evaluate
ILVT, ECG, signal-averaged ECG, Holter monitoring
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during sport activity, exercise test, echocardiography,
coronary angiography, magnetic resonance imaging
and EPS can be used.
Recommendation
See recommendations for right ventricular outflow
tract tachycardia.
Bundle branch reentry ventricular tachycardia
Prognosis of athletes with this form of tachycardia is
related to the severity of left ventricular dysfunction
and the underlying disease (for instance HCM). The
electrocardiographic features are LBBB morphology,
although an RBBB variant is also described. In most
cases-the His bundle is involved in the disease process
and the HV interval in sinus rhythm exceeds 80 ms
during EPS. In general RF ablation abolishes the VT.
Evaluation can be carried out using ECG, signal-
averaged ECG, Holter monitoring during sport
activity, exercise test, echocardiography, coronary
angiography, magnetic resonance imaging and EPS.
Recommendation
Athletes may participate in class IA sports but no
competitive sports.'4
Polymorphic VT
Usually the disorder emerges at an early age, but more
adult onset has been described. Patients present with
recurrent syncope triggered by exercise. Exercise may
evoke polymorphic VT/VF in patients with cate-
cholamine sensitive polymorphic VT/VF. It typically
occurs with isolated atrial and ventricular ectopy at a
certain (rate) threshold, followed by bi-directional
doublets and more complex polymorphic VT or VF.
QT interval is normal. A family history for SCD is
common. EPS with isoproterenol infusion provokes
this type of arrhythmia. In some cases it is a primarily
electrical autosomal dominant inherited disorder
(LQTS, Brugada syndrome, etc) or there could be an
underlying structural heart disease (cardiomyopathy
or ARVD). Evaluation is with ECG, signal-averaged
ECG, Holter monitoring during sport activity, exercise
test, echocardiography, coronary angiography and
EPS.
Recommendation
Athletes with polymorphic ventricular tachycardias,
with structural heart disease in combination with PVCs,
nonsustained and sustained VT, may only participate
in low-intensity sports (class IA) whether the VT is
suppressed or not. In athletes with ICD, all moderate
and high-intensity sports are contraindicated. These
athletes may participate in class IA sports.9
Summary
For diagnosis ofstructural heart disease, screening of
all athletes who may be a risk factor for sudden cardiac
death is not feasible and therefore not advisable. From
a practical point ofview the physician has to make a
selection in order to pursue the best protection for
the individual athlete. The physician should take into
account the age-frequency distribution of causes of
sudden cardiac death (figure 1). A good specific
medical history addresses chest discomfort, dyspnoea,
light-headedness, palpitations and early fatigue out of
proportion to the level of exercise, which can be
suggestive of underlying heart disease. A history of
near syncope, and syncope during exercise or at rest
in athletes warrants further evaluation. Syncope may
be benign but can also be the first sign of a serious
structural heart disease and could be a predictive sign
of sudden cardiac death. A family history of sudden
cardiac death is very useful in identifying athletes at
risk. Physical examination can sometimes identify
risk-bearing athletes or diseases, such as Marfan's
Figure 1. Agefrequency distribution ofvarious aetiologies ofsudden cardiac death (adaptedfrom refrrence 23).
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syndrome (leptosome athletes), HCM or aortic of asymptomatic and symptomatic athletes in the
stenosis and constitute a substantial risk for sudden assessment of eligibility for competitive sports. Pre-
death. syncope or syncope and/or sudden cardiac death are
more likely to occur in the presence of underlying
Proposalsfor recommendations and protocols heart disease. A syncope is a very important event and
The following recommendations are made for car- should be considered as an aborted sudden death
diologists in order to support and guide the selection until proven otherwise. The underlying mechanism
Netherlands Heart Journal, Volume 12, Number 5, May 2004
Table 1. Cardiovascular screening questionnaire.
One positive answer justifies a specialised cardiovascular evaluation and advice.
1 Have you ever undergone surgery to the heart or great vessels?
2 Have you ever been diagnosed with a cardiac anomaly?
3 Have you ever been treated for a cardiovascular disease?
4 Are you taking any cardiovascular medication? (Antihypertensive drugs, anticoagulation, antiarrhythmic drugs)
5 Has any member of your family died suddenly before the age of 35?
6 Do you have a family history of hypertrophic cardiomyopathy?
7 Is there anyone in your family aged <35 with an ICD or pacemaker implant?
8 Do you have chest pain during exercise which rapidly disappears after cessation of exercise?
9 Have you ever had palpitations (see*)?
10 Have you ever had presyncope or a syncopal episode (see **)?
11 Have you ever been diagnosed with hypertension?
12 Is there a blood pressure difference of more than 15 mmHg between both arms?
13 Are the femoral pulses absent or asymmetric? Has anyone ever noticed a murmur in the groin?
15 Is a fourth heart sound present?
16 Is a diastolic heart murmur present?
17 Is a systolic heart murmur present that does not seem to be physiological?
18 Is a fixed splitting of the second heart sound present?
19 Is there a resting heart rate of less than 40 beats/min on clinical examination?
20 Did you find any stigmata of Marfan's disease on clinical examination?
(*) Palpitations: Inappropriate rapid heartbeat of more than 130 beats/min, regular or irregular, variable in duration, with or without associated symptoms
(vertigo, chest pain, shortness of breath, syncope or presyncope.) Sudden onset? Regular or irregular? Frequency? Duration of this episode? How often are
palpitations present? Precipitating factors? How did it stop?
(**) (Pre)syncope: Sudden decrease or loss of consciousness often preceded by acute vertigo or loss of vision.
Table 2. Stress testing protocol for screening athletes with suspected arrhythmias.
Cyclist
Warming up for 3 minutes with a loading of 2 watt/kg.
After three minutes increase the loading every minute by 20 watt until exhaustion.
Three minutes rest.
Sprint protocol: increase loading in 2 minutes to 1000 watt; this sprint protocol should be done twice. Between the 2 sprints,
2 minutes rest.
Two-minute loading of 85 to 90% of the maximal power between the 2-minute periods, 1 minute with a loading of 100 watt.
The 2-minute loading can be repeated 2 or 3 times.
Running athlete
Warming up for 2 minutes at a speed 8 km/h.
After the 5-minute period increase the speed by 1 km/h every minute until exhaustion.
Three minutes rest.
Sprint protocol: Increase the speed in 2 minutes until maximum speed. Between the 2 sprints a 3-minute rest should be scheduled.
Two-minute loading of 85 to 90% of the maximal speed, between the loadings a 2-minute period with a speed of 8 km/h is
scheduled. The 2-minute loading can be repeated 2 or 3 times.
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has to be elucidated. If there is a suspicion of
arrhythmias, great pains should to be taken in
provoking and monitoring the cardiac rhythm. The
cardiologist must be aware that arrhythmias can be
benign but can also be the first sign ofan underlying
heart disease. The behaviour ofthe arrhythmia during
sport activity should be assessed. Both brady-
arrhythmia and tachyarrhythmia can be incompatible
with athletic performance and could induce non-
acceptable high risks for the athlete himselfor others.
Still worse, the initial innocent arrhythmia can pro-
voke a dangerous new one.
To evaluate eligibility for (competitive) sport in
symptomatic or asymptomatic athletes, the arrhythmo-
logical evaluation can be divided into three levels.
Level I Includes:
- The cardiovascular screening questionnaire
(table 1).24
- A physical examination with special attention to
stigmata ofMarfan's syndrome. Is there a difference
in blood pressure ofmore then 15 mmHg in both
arms? On cardiac auscultation, is there a murmur
in diastole or a nonphysiological systolic murmur?
Any abnormal splitting ofthe second heart sound?
Heart rate below 40 beats/min? Pulsations in both
femoral arteries symmetric?
- ECG (rest and exercise).
Figure 2. Estimatedprevalence ofsudden cardiac death in athletes
younger than 35.
Level 11 Includes:
- ECG.
- Echocardiography M-mode, 2D and colour-flow
Doppler.
- Holter monitoring should be performed during
periods of intense physical activity and preferably
whenever the athlete is performing her or his
specific sport activity.
- 12-lead stress tests (sport specific) with a special
protocol (table 2.) A normal stress test protocol
for screening coronary artery disease in a young
athletic population is not adequate.
- Routine blood test.
Level Ill Includes:
- Signal-averaged ECG.
- Echocardiography M-mode, 2D, and colour-flow
Doppler.
- Magnetic resonance imaging (MRI).
- Left and right catheterisation, left and right
ventriculography and coronary angiography.
- Head-up tilt testing.
- EPS (table 3.)
- Nuclear stress test.
In the assessment of eligibility for competitive sport
the cardiologist should take into account the age of
the athlete (figure 1), level ofathletic performance and
impact ofdifferent sports on the cardiovascular system.
Protocol for asymptomatic athletes (all ages)
Cardiological evaluation level I is applied if there is a
negative specific medical history, no abnormalities on
physical examination, and no abnormal findings in the
ECG and no history ofsudden cardiac death no further
evaluation is necessary and the athlete may participate
in all competitive sports.
Level II evaluation should be done in case of
abnormalities on the ECG to exclude HCM or other
structural heart diseases.
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Table 3. Indications for EPS.
All supraventricular reentry and focal tachycardias:
- WPW syndrome asymptomatic, at risk, or symptomatic
- Atrial flutter
- Idiopathic, right or left ventricular tachycardia
- Ventricular tachycardia in relation to structural heart dis-
ease, such as ARVD, DCM, etc
Cardiac hypertrophy
o-~ 10%Coronary
I Ruptured aorta
5%
Tunnelled LAD
5%
Aortic stenosis
4%
Myocarditis 3%
DCM 3%
ARVD 3%
MVP 2%
CAD 2%
Other
6%
Table 4. Cardiac and noncardiac causes of sudden cardiac
death.17
HCM Arteriovenous anomaly
CAD WPW
ARVD Myocardial bridging
CM Coronary aneurysm
LVH Subvalvular aortic stenoses
Myocarditis LQTS
Conduction disorder Idiopathic VF
Mitral valve prolapse DCM
Valve disease Cerebral embolus
Aorta dissection Pulmonary embolus
HCM=hypertrophic cardiomyopathy, CAD=coronary artery disease,
ARVD=arrhythmic right ventricular cardiomyopathy, CM=congenital
coronary artery anomalies, LVH=left ventricular hypertrophy, WPW=Wolff-
Parkinson-White syndrome, LQTS=long4T syndrome, VF=ventricular
fibrillation, DCM=dilated cardiopathy.
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Recommendations and cardiological evaluation of athletes with arrhythmias
If there is a suspect family history of sudden cardiac
death and/or structural heart disease, level II and in
certain cases level III cardiological evaluation is in-
dicated.
Protocolfor symptomatic athletes age <35year
Full cardiac evaluation is indicated with special attention
to the most prominent cardiac disorders in relation to
sudden cardiac death (figure 2 and table 4).
Protocolfor symptomatic athletes age >35year
Full cardiac evaluation is indicated with special attention
to coronary artery disease. a
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